Intravenous Allopurinol in Heart Failure
Recruitment status was Recruiting
This study tests the hypothesis that allopurinol, a xanthine oxidase inhibitor, improves heart metabolism in patients with heart failure.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Investigator)
|Official Title:||Effects of Xanthine Oxidase Inhibition on Mechano-Energetic Coupling in Heart Failure|
- Myocardial CK flux [ Time Frame: acute (within 60 minutes of single infusion) ] [ Designated as safety issue: No ]The mean rate of ATP flux through the creatine kinase reaction in the heart. The units for this measure are: umol/g/sec.
- Cardiac PCr/ATP [ Time Frame: acute (within 60 minutes of single infusion) ] [ Designated as safety issue: No ]The mean ratio of creatine phosphate (PCr) to ATP in the heart. This measure, as a ratio, is unitless.
|Study Start Date:||November 2004|
|Estimated Study Completion Date:||December 2010|
|Estimated Primary Completion Date:||May 2009 (Final data collection date for primary outcome measure)|
Drug: allopurinol 300mg intravenous
Xanthine oxidase have been reported to improve mechano-energetic coupling in failing hearts. The investigators developed a means to directly measure creatine kinase flux, the major energy reserve of the heart, in the human heart exploiting new magnetic resonance technologies.
The investigators propose to study 10 healthy subjects and up to 25 with heart failure (dilated cardiomyopathy) before and after a single 300mg IV infusion of allopurinol.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00181155
|Contact: Robert G Weiss, MDemail@example.com|
|United States, Maryland|
|Johns Hopkins Hospital||Recruiting|
|Baltimore, Maryland, United States, 21287|
|Contact: Tricia Steinberg, RN 443-287-3469 firstname.lastname@example.org|
|Principal Investigator:||Robert G Weiss, MD||Johns Hopkins University|